Mechanisms by which common variants in the TCF7L2 gene increase risk of type 2 diabetes.

By V. Lyssenko, R. Lupi, P. Marchetti, S. del Guerra, M. Orho-Melander, P. Almgren, M. Sjögren, C. Ling, K. Eriksson, ÅsaLinda Lethagen and 6 more. Journal of Clinical Investigation, 2007

839 citations recorded by the source corpus.

Subfields: Endocrinology, Diabetes and Metabolism, Genetics, Surgery

View Paper: https://www.semanticscholar.org/paper/511b89dc0f8fdb5f4cd69c6959583688ebab19de

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Endocrinology, Diabetes and Metabolism

1. F. Alsaraj
2. Ralph DeFronzo
3. Josephine M. Egan
4. Wook Kim
5. I. Tabas
6. K. Bornfeldt

In Genetics

1. Ralph DeFronzo

In Surgery

1. F. Alsaraj
2. Ralph DeFronzo
3. Josephine M. Egan
4. Wook Kim

Citations in the corpus

• From the Triumvirate to the Ominous Octet: A New Paradigm for the Treatment of Type 2 Diabetes Mellitus (2009, background): “Studies by Groop and colleagues (63) have shown that the T-allele of single nucleotide polymorphism rs7903146 of the TCF7L2 gene is associated with impaired insulin secretion in vivo and reduced responsiveness to glucagon-like peptide 1 (GLP-1).”
• TCF/LEFs and Wnt signaling in the nucleus. (2012, background): “The strongest diabetes-associated polymorphism identified to date occurs in an intervening sequence of the TCF4/TCF7L2 gene (Grant et al. 2006; Lyssenko et al. 2007; and reviewed in Doria et al. 2008).”
• Pathogenesis of Type 2 Diabetes Mellitus (2015, background): “The risks of alleles in TCF7L2 were associated with hepatic but not peripheral IR and enhanced the rate of hepatic glucose production in human [162].”
• The Role of Incretins in Glucose Homeostasis and Diabetes Treatment (2008, background): “This is very interesting from a clinical standpoint because genetic studies have linked the risk for T2DM to TCF7L2 polymorphisms (Lyssenko et al., 2007).”